参考文献/References:
[1] Unger T,Borghi C,Charchar F,et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines[J]. Hypertension,2020,75(6):1334-1357.
[2] Seravalle G,Grassi G. Sympathetic nervous system and hypertension:new evidences[J]. Auton Neurosci,2022,238:102954.
[3] Azizi M,Saxena M,Wang Y,et al. Endovascular ultrasound renal denervation to treat hypertension:the RADIANCE Ⅱ randomized clinical trial[J]. JAMA,2023,329(8):651-661.
[4] Bhatt DL,Vaduganathan M,Kandzari DE,et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension:final follow-up of the randomised SYMPLICITY HTN-3 trial[J]. Lancet,2022,400(10361):1405-1416.
[5] Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension:a multicentre safety and proof-of-principle cohort study[J]. Lancet,2009,373(9671):1275-1281.
[6] Symplicity HTN-2 Investigators,Esler MD,Krum H,et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial):a randomised controlled trial[J]. Lancet,2010,376(9756):1903-1909.
[7] Bhatt DL,Kandzari DE,O’Neill WW,et al. A controlled trial of renal denervation for resistant hypertension[J]. N Engl J Med,2014,370(15):1393-1401.
[8] Townsend RR,Mahfoud F,Kandzari DE,et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED):a randomised,sham-controlled,proof-of-concept trial[J]. Lancet,2017,390(10108):2160-2170.
[9] Kandzari DE,B?hm M,Mahfoud F,et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial[J]. Lancet,2018,391(10137):2346-2355.
[10] 李月平,卢成志,蒋雄京,等. 经皮去肾神经术治疗高血压中国专家科学声明[J]. 中国介入心脏病学杂志,2023,31(12):881-893.
[11] Azizi M,Schmieder RE,Mahfoud F,et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre,international,single-blind,randomised,sham-controlled trial[J]. Lancet,2018,391(10137):2335-2345.
[12] Azizi M,Sanghvi K,Saxena M,et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO):a randomised,multicentre,single-blind,sham-controlled trial[J]. Lancet,2021,397(10293):2476-2486.
[13] Lauder L,Mahfoud F. Adherence to antihypertensive medication in renal denervation trials:new studies,old problems?[J]. Hypertens Res,2023,46(11):2543-2544.
[14] Pathak A,Rudolph UM,Saxena M,et al. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications[J]. EuroIntervention,2023,19(7):602-611.
[15] Kandzari DE,Weber MA,Pathak A,et al. Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications:primary results from the TARGET BPⅠ randomized clinical trial[J]. Circulation,2024,149(24):1875-1884.
[16] Fengler K,Rommel KP,Blazek S,et al. A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN)[J]. Circulation,2019,139(5):590-600.
[17] Ogoyama Y,Abe M,Okamura K,et al. Effects of renal denervation on blood pressure in patients with hypertension:a latest systematic review and meta-analysis of randomized sham-controlled trials[J]. Hypertens Res,2024.DOI:10.1038/s41440-024-01739-y.Online ahead of print.
[18] Desch S,Okon T,Heinemann D,et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension[J]. Hypertension,2015,65(6):1202-1208.
[19] Mathiassen ON,Vase H,Bech JN,et al. Renal denervation in treatment-resistant essential hypertension. A randomized,SHAM-controlled,double-blinded 24-h blood pressure-based trial[J].?J Hypertens,2016,34(8):1639-1647.
[20] B?hm M,Kario K,Kandzari DE,et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal):a multicentre,randomised,sham-controlled trial[J].?Lancet,2020,395(10234):1444-1451.
[21] Kandzari DE,Townsend RR,Kario K,et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications[J]. J Am Coll Cardiol,2023,82(19):1809-1823.
[22] Wang J,Yin Y,Lu C,et al. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART):6-month follow-up of a randomised,controlled trial[J]. EClinicalMedicine,2024,72:102626.
[23] Kario K,Yokoi Y,Okamura K,et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension:the randomized,controlled REQUIRE trial[J]. Hypertens Res,2022,45(2):221-231.
[24] Sharp ASP,Sanderson A,Hansell N,et al. Renal denervation for uncontrolled hypertension:a systematic review and meta-analysis examining multiple subgroups[J]. J Hypertens,2024,42(7):1133-1144.
[25] Messerli FH,Schoenenberger-Berzins R,Messerli AW. Why the lack of enthusiasm for renal denervation?[J]. J Hypertens,2024,42(7):1145-1146.
[26] Mahfoud F,B?hm M,Schmieder R,et al. Effects of renal denervation on kidney function and long-term outcomes:3-year follow-up from the Global SYMPLICITY Registry[J]. Eur Heart J,2019,40(42):3474-3482.
[27] Mahfoud F,Kandzari DE,Kario K,et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED):a randomised,sham-controlled trial[J]. Lancet,2022,399(10333):1401-1410.
[28] Zeijen VJM,Feyz L,Nannan Panday R,et al. Long-term follow-up of patients undergoing renal sympathetic denervation[J]. Clin Res Cardiol,2022,111(11):1256-1268.
[29] Sesa-Ashton G,Nolde JM,Muente I,et al. Catheter-based renal denervation:9-year follow-up data on safety and blood pressure reduction in patients with resistant hypertension[J]. Hypertension,2023,80(4):811-819.
[30] Al Ghorani H,Kulenthiran S,Recktenwald MJM,et al. 10-Year outcomes of catheter-based renal denervation in patients with resistant hypertension[J]. J Am Coll Cardiol,2023,81(5):517-519.
[31] Wang L,Li C,Li Z,et al. Ten-year follow-up of very-high risk hypertensive patients undergoing renal sympathetic denervation[J].?J Hypertens,2024,42(5):801-808.
[32] Booth LC,Nishi EE,Yao ST,et al. Reinnervation of renal afferent and efferent nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep[J]. Hypertension,2015,65(2):393-400.
[33] Singh RR,McArdle ZM,Iudica M,et al. Sustained decrease in blood pressure and reduced anatomical and functional reinnervation of renal nerves in hypertensive sheep 30 months after catheter-based renal denervation[J]. Hypertension,2019,73(3):718-727.
[34] Kario K,B?hm M,Mahfoud F,et al. Twenty-four-hour ambulatory blood pressure reduction patterns after renal denervation in the SPYRAL HTN-OFF MED trial[J]. Circulation,2018,138(15):1602-1604.
[35] Kario K,Mahfoud F,Kandzari DE,et al. Long-term reduction in morning and nighttime blood pressure after renal denervation:36-month results from SPYRAL HTN-ON MED trial[J]. Hypertens Res,2023,46(1):280-288.
[36] Bakris GL,Townsend RR,Liu M,et al. Impact of renal denervation on 24-hour ambulatory blood pressure:results from SYMPLICITY HTN-3[J]. J Am Coll Cardiol,2014,64(11):1071-1078.
[37] Gosse P,Cremer A,Pereira H,et al. Twenty-four-hour blood pressure monitoring to predict and assess impact of renal denervation:the DENERHTN study (renal denervation for hypertension)[J]. Hypertension,2017,69(3):494-500.
[38] Cai H,Fang Z,Lin R,et al. Insight on efficacy of renal artery denervation for refractory hypertension with chronic kidney diseases:a long-term follow-up of 24-hour ambulatory blood pressure[J]. J Interv Cardiol,2022,2022:6895993.
[39] Mahfoud F,Bakris G,Bhatt DL,et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension:data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry[J]. Eur Heart J,2017,38(2):93-100.
[40] Mahfoud F,Mancia G,Schmieder R,et al. Renal denervation in high-risk patients with hypertension[J]. J Am Coll Cardiol,2020,75(23):2879-2888.
[41] Fengler K,Rommel KP,Lapusca R,et al. Renal denervation in isolated systolic hypertension using different catheter techniques and technologies[J]. Hypertension,2019,74(2):341-348.
[42] Kordalis A,Tsiachris D,Pietri P,et al. Regression of organ damage following renal denervation in resistant hypertension:a meta-analysis[J]. J Hypertens,2018,36(8):1614-1621.
[43] Dai Z,Yu S,Zhao Q,et al. Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model[J]. EuroIntervention,2014,10(3):392-399.
[44] Eriguchi M,Tsuruya K,Haruyama N,et al. Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease[J]. Kidney Int,2015,87(1):116-127.
[45] Sanders MF,Reitsma JB,Morpey M,et al. Renal safety of catheter-based renal denervation:systematic review and meta-analysis[J]. Nephrol Dial Transplant,2017,32(9):1440-1447.
[46] Xia M,Liu T,Chen D,et al. Efficacy and safety of renal denervation for hypertension in patients with chronic kidney disease:a meta-analysis[J]. Int J Hyperthermia,2021,38(1):732-742.
[47] Ott C,Mahfoud F,Mancia G,et al. Renal denervation in patients with versus without chronic kidney disease:results from the Global SYMPLICITY Registry with follow-up data of 3 years[J]. Nephrol Dial Transplant,2022,37(2):304-310.
[48] Burnier M. Renal denervation for patients with chronic kidney disease and resistant hypertension:effective and safe but still not the panacea[J]. Nephrol Dia Transplant,2022,37(2):208-210.
[49] Solbu MD,Miroslawska A,Norvik JV,et al. Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The reshape CV-risk study[J]. J Clin Hypertens(Greenwich),2021,23(5):954-962.
[50] Wang Y,Rijal B,Xu M,et al. Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance[J]. Acta Diabetol,2020,57(10):1227-1243.
[51] Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure:an individual participant-level data meta-analysis[J]. Lancet,2021,397(10285):1625-1636.
[52] Lauder L,Kandzari DE,Lüscher TF,et al. Renal denervation in the management of hypertension[J]. EuroIntervention,2024,20(8):e467-e478.
[53] Mahfoud F,Mancia G,Schmieder RE,et al. Cardiovascular risk reduction after renal denervation according to time in therapeutic systolic blood pressure range[J]. J Am Coll Cardiol,2022,80(20):1871-1880.
[54] Castillo Rodriguez B,Secemsky EA,Swaminathan RV,et al. Opportunities and limitations of renal denervation:where do we stand?[J]. Am J Med,2024,137(8):712-718.
[55] Silvinato A,Floriano I,Bernardo WM. Renal denervation by radiofrequency in patients with hypertension:systematic review and meta-analysis[J]. Rev Assoc Med Bras (1992),2024,70(4):e2023D704.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[11]李昱熙 张震 余静 蒋雄京.去肾神经治疗高血压的临床前景和探索方向[J].心血管病学进展,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
LI YuxiZHANG ZhenYU JingJIANG Xiongjing.Future of Renal Denervation on Hypertension Therapy[J].Advances in Cardiovascular Diseases,2024,(10):865.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.001]
[12]陈晓平,左祥浩,叶涛,等.当前经导管去肾神经术治疗高血压面临的挑战[J].心血管病学进展,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
CHEN Xiaoping,ZUO Xianghao,YE Tao,et al.Current Challenges of Transcatheter Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):870.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.002]
[13]亢园园 罗淞元 许建忠 罗建方 卢成志.当前不同去肾神经术的特点和存在的问题[J].心血管病学进展,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
KANG yuanyuan,LUO Songyuan,XU Jianzhong,et al.The Mechanisms and Future Challenges of Different Renal Denervation Therapy[J].Advances in Cardiovascular Diseases,2024,(10):875.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.003]
[14]王沛坚 陈威 董徽 马为.中国自主研发RDN器械治疗高血压临床试验数据的特色[J].心血管病学进展,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
WANG Peijian,CHEN Wei,DONG Hui,et al.Characteristics of Clinical Trial Data of RDN Devices Independently Developed in China[J].Advances in Cardiovascular Diseases,2024,(10):880.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.004]
[15]封欣妤 张冬颖 邹玉宝 冯颖青 程康.如何选择去肾神经术治疗高血压的最适宜人群[J].心血管病学进展,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]
FENG Xinyu,ZHANG Dongying,ZOU Yubao,et al.How to Select the Optimal Population for Renal Denervation in the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2024,(10):885.[doi:10.16806/j.cnki.issn.1004-3934.2024.10.005]